@article{bf98b25cfc7146238243840c088f21e1,
title = "Lewy Body Dementia Association{\textquoteright}s Industry Advisory Council: proceedings of the second annual meeting",
abstract = "In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments. At the second annual meeting of the Industry Advisory Council, held virtually on June 18, 2020, the key members presented ongoing and planned efforts toward the council{\textquoteright}s goals. The meeting also featured a discussion about the effects of the COVID-19 pandemic on Lewy body dementia clinical research, lessons learned from that experience, and how those lessons can be applied to the design and conduct of future clinical trials. This report provides a brief summary of the meeting proceedings with a focus on efforts to improve and adapt future Lewy body dementia clinical research.",
keywords = "COVID-19, Clinical trial, Lewy body dementia, Research, Telemedicine",
author = "Goldman, {Jennifer G.} and Boeve, {Bradley F.} and Armstrong, {Melissa J.} and Galasko, {Doug R.} and Galvin, {James E.} and Irwin, {David J.} and Leverenz, {James B.} and Karen Marder and Victor Abler and Kevin Biglan and Irizarry, {Michael C.} and Bill Keller and Robert Lai and Leanne Munsie and Michael Belleville and Ondrea Chaney and Ian Richard and Angela Taylor and Todd Graham",
note = "Funding Information: Boeve, B has served as an investigator for clinical trials sponsored by Biogen, Alector, and EIP Pharma. He serves on the Scientific Advisory Board of the Lewy Body Dementia Association, Association for Frontotemporal Degeneration, and Tau Consortium. He receives research support from the NIH, the Mayo Clinic Dorothy and Harry T. Mangurian Jr. Lewy Body Dementia Program, and the Little Family Foundation. He serves as the coordinating center director for the Lewy Body Dementia Association Research Center of Excellence. Funding Information: Galvin, JE serves on the Board of Directors for the Lewy Body Dementia Association, Lewy Body Resource Center, and the Southeast Florida Chapter of the Alzheimer Association; serves as a consultant for Biogen and Medivante-Prophase; performs clinical and cognitive evaluations in his clinical practice (15% effort) and bills for these procedures; is funded by NIH grants (R01 AG040211, R01 NS1010483, R01 AG057681, P30 AG059295, U01 NS100610, U54 AG063546, R01 AG056610, R01 AG054425, R01 AG056531, R01 AG040211, R01 NS1010483, R01 AG057681, P30 AG059295, U01 NS100610, U54 AG063546, R01 AG056610, R01 AG054425, and R01 AG056531) and by the Harry T. Mangurian Foundation and the Leo and Anne Albert Charitable Trust; and receives research support as director and principal investigator of the Lewy Body Dementia Research Center of Excellence from the Lewy Body Dementia Association. Funding Information: Marder, K has received funding from NIH (NS100600 (MPI), U24NS107168 (MPI), UL1TR001873, NS095435, LM009886, MH230794), the Lewy Body Dementia Association, CHDI, Huntington{\textquoteright}s Disease Society of America, Parkinson{\textquoteright}s Disease Foundation, Michael J. Fox, and Springer LTD (section editor). She is a site investigator for Genentech, Triplet Therapeutics, and Prilenia. Funding Information: Irwin, DJ is supported by grants from NINDS (NS109260), NIA (AG010124, U19-AG062418 P01-AG066597), and Penn Institute on Aging. He is an investigator for the Lewy Body Dementia Association Research Center of Excellence at Penn. Funding Information: Armstrong, MJ is supported by grants from the NIA (P30AG047266, R01AG068128) and the Florida Department of Health (grant 20A08). She previously received compensation from the AAN for work as an evidence-based medicine methodology consultant and is on the level of evidence editorial board for Neurology{\textregistered} and related publications (uncompensated). She serves as an investigator for the Lewy Body Dementia Association Research Center of Excellence. Funding Information: Galasko, D receives research support from the NIH, State of California, Michael J. Fox Foundation, and the Alzheimer{\textquoteright}s Drug Discovery Foundation. He is a consultant for Biogen, Amprion, Fujirebio, General Electric Healthcare, Generion, and Cognition Therapeutics and is the Editor-in-Chief of Alzheimer{\textquoteright}s Research & Therapy. Funding Information: Leverenz, J has received grant/research funding from NIH (P30 AG062428, U01 NS100610, R01 AG022304, R01AG0577552, RF1AG051495, R21AG064271, P20AG068053), the Jane and Lee Seidman Endowed Chair for Advanced Neurological Research and Education, Douglas Herthel DVM Memorial Fund, and GE Healthcare and has received consultant fees from Biogen, Citibank, and Eisai. He serves as the director for the Cleveland Clinic Lewy Body Dementia Association Research Center of Excellence. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = dec,
doi = "10.1186/s13195-021-00868-7",
language = "English (US)",
volume = "13",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",
}